Novel therapeutic agent for prionoid diseases
US-2019358276-A1 · Nov 28, 2019 · US
Anticancer agent comprising HVJ-E and immune checkpoint protein inhibitor
US11166995B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11166995-B2 |
| Application number | US-201716346576-A |
| Country | US |
| Kind code | B2 |
| Filing date | Nov 1, 2017 |
| Priority date | Nov 1, 2016 |
| Publication date | Nov 9, 2021 |
| Grant date | Nov 9, 2021 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention provides an anticancer agent containing the following (1) and (2):(1) HVJ-E (hemagglutinating virus of Japan envelope),(2) an inhibitor of an immune checkpoint protein.
First claim
Opening claim text (preview).
The invention claimed is: 1. A method for slowing the progression of melanoma, mesothelioma, or prostate cancer, comprising administering multiple doses of an effective amount of HVJ-E and anti-PD-1 antibody RMP1-14 to a subject, thereby slowing the progression of melanoma, mesothelioma, or prostate cancer in the subject. 2. The method according to claim 1 , wherein HVJ-E and anti-PD-1 antibody RMP1-14 are administered to the subject in the form of a pharmaceutical composition that comprises both HVJ-E and anti-PD-1 antibody RMP1-14. 3. The method according to claim 1 , wherein HVJ-E and anti-PD-1 antibody RMP1-14 are administered to the subject in the form of a first pharmaceutical composition that comprises HVJ-E and a second pharmaceutical composition that comprises anti-PD-1 antibody RMP1-14 and that is not the same as the first pharmaceutical composition. 4. The method according to claim 1 , wherein the subject is a human that has melanoma, and the administration of multiple doses of an effective amount of HVJ-E and anti-PD-1 antibody RMP1-14 slows the progression of melanoma in the subject. 5. The method according to claim 1 , wherein the subject is a human that has mesothelioma, and the administration of multiple doses of an effective amount of HVJ-E and anti-PD-1 antibody RMP1-14 slows the progression of mesothelioma in the subject. 6. The method according to claim 1 , wherein the subject is a human that has prostate cancer, and the administration of multiple doses of an effective amount of HVJ-E and anti-PD-1 antibody RMP1-14 slows the progression of prostate cancer in the subject.
Assignees
Inventors
Classifications
Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca · CPC title
Demonstrated in vivo effect · CPC title
Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein · CPC title
wherein the target is cancer · CPC title
inactivated (killed) · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US11166995B2 cover?
- The present invention provides an anticancer agent containing the following (1) and (2):(1) HVJ-E (hemagglutinating virus of Japan envelope),(2) an inhibitor of an immune checkpoint protein.
- Who is the assignee on this patent?
- Univ Osaka, Genomidea Inc
- What technology area does this patent fall under?
- Primary CPC classification A61P35/00. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Nov 09 2021 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 2 related publications on this page (citations in our corpus or others sharing the same primary CPC).